PASITHEA THERAPEUTICS CORP
KTTANASDAQTrading Snapshot
- Day Range
- $0.47 β $0.48
- 52-Week Range
- $0.28 β $2.06
- Volume (shares)
- 100,722
- Avg Volume (shares)
- β
- Shares Outstanding
- 33.4M
- Next Earnings
- 2027-03-29
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- β
- P/S Ratio
- 26.8x
- EPS (TTM)
- $-1.48
- Dividend Yield
- β
- Dilution (1yr)
- +541.5%
PASITHEA THERAPEUTICS CORP
KTTAAbout PASITHEA THERAPEUTICS CORP
Pasithea Therapeutics Corp. functions as a biotechnology firm dedicated to the discovery and advancement of novel therapeutic solutions for various psychiatric and neurological conditions. Beyond its research endeavors, the company also plans to establish and manage clinics specializing in depression treatment. These facilities are designed to offer business support, employing trained pharmacists to administer intravenous ketamine infusions. Founded in 2020, the corporation's primary operations are based in Miami Beach, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Latest News & Updates

Pasithea's PAS-004 Shrinks Skin Tumors in All 15 Evaluable Patients
Pasithea Therapeutics Corp. (NASDAQ:KTTA) on Friday shared positive clinical data from its Phase 1/1b study of PAS-004 in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and cutaneous n

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference
Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activi

Pasithea Therapeutics Announces FDA Clearance of IND for PAS-004 in Neurofibromatosis Type 1 (NF1)-Associated Cutaneous Neurofibromas (cNF)
β FDA clearance allows Pasithea to advance PAS-004 for NF1-associated cNF, a condition affecting over 95% of people with NF1 and for which there are currently no FDA-approved systemic therapies . β MIAMI, Nov. 03, 2026 (

Pasithea Therapeutics to Host Virtual KOL Event on NF1 Treatment November 4, 2026
MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (βPasitheaβ or the βCompanyβ), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibit

Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026
-- Prolonged Stable Disease: PAS-004 achieved prolonged stable disease in a heavily pre-treated population, with four patients on PAS-004 for more than 300 days, including two who continue on once daily PAS-004 for over

Pasithea Therapeutics (NASDAQ:KTTA) Shares Down 2.7% β Time to Sell?
Pasithea Therapeutics Corp. (NASDAQ: KTTA - Get Free Report) shares dropped 2.7% on Friday. The company traded as low as $0.4748 and last traded at $0.4760. Approximately 59,809 shares were traded during mid-day trading,